Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study

Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study

Background: Erlotinib-based combination therapy leads to increased efficacy but also toxicity for EGFR-mutated NSCLC. Reducing the dose of erlotinib could improve treatment tolerability, but few evidences are available regarding its efficacy at reduced dose. This randomized phase-2 study intends to...

Full description

Bibliographic Details
Main Authors: Shen Zhao, Zhen Zhang, Wenfeng Fang, Yaxiong Zhang, Zhonghan Zhang, Shaodong Hong, Yuxiang Ma, Ting Zhou, Yunpeng Yang, Yan Huang, Hongyun Zhao, Li Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer
randomized controlled trial
lower dose
erlotinib
gefitinib
EGFR mutation
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.587849/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.587849/full

Similar Items